Avorelin
| Code | Size | Price |
|---|
| TAR-T26692-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Avorelin, a luteinizing hormone releasing hormone (LH-RH) agonist, is used potentially for the treatment of prostate.
CAS:
140703-49-7
Formula:
C65H85N17O12
Molecular Weight:
1296.502
Purity:
0.98
SMILES:
CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc1c(C)[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1
References
1. Kaisary AV, Bowsher WG, Gillatt DA, Anderson JB, Malone PR, Imbimbo BP. Pharmacodynamics of a long acting depot preparation of avorelin in patients with prostate cancer. Avorelin Study Group. J Urol. 1999 Dec;162(6):2019-23. PubMed PMID: 10569560.
2. Brown GR, Dixson AF. Investigation of the role of postnatal testosterone in the expression of sex differences in behavior in infant rhesus macaques (Macaca mulatta). Horm Behav. 1999 Apr;35(2):186-94. PubMed PMID: 10202126.
3. Brown GR, Nevison CM, Fraser HM, Dixson AF. Manipulation of postnatal testosterone levels affects phallic and clitoral development in infant rhesus monkeys. Int J Androl. 1999 Apr;22(2):119-28. PubMed PMID: 10194644.